Jiangsu Hualan New Pharmaceutical MaterialLtd Management
Management criteria checks 4/4
Jiangsu Hualan New Pharmaceutical MaterialLtd's CEO is Yimin Hua, appointed in Oct 2009, has a tenure of 15.17 years. directly owns 6.01% of the company’s shares, worth CN¥166.57M. The average tenure of the management team and the board of directors is 2.7 years and 6.2 years respectively.
Key information
Yimin Hua
Chief executive officer
CN¥1.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 15.2yrs |
| CEO ownership | 6.0% |
| Management average tenure | 2.7yrs |
| Board average tenure | 6.2yrs |
CEO
Yimin Hua (42 yo)
15.2yrs
Tenure
CN¥1,030,000
Compensation
Mr. Yimin Hua serves as the General Manager and Director at Jiangsu Hualan New Pharmaceutical Material Co., Ltd since October 9, 2009 and has been its Chairman since March 22, 2022.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | 15.2yrs | CN¥1.03m | 6.01% CN¥ 166.6m | |
| Financial Director & Deputy GM | 5.5yrs | CN¥670.00k | 0.081% CN¥ 2.2m | |
| Deputy GM & Director | 8yrs | CN¥445.10k | 0.23% CN¥ 6.3m | |
| Deputy GM & Secretary of the Board | 2.7yrs | CN¥410.00k | 0.12% CN¥ 3.4m | |
| Deputy General Manager | 2.7yrs | CN¥490.00k | 0.040% CN¥ 1.1m | |
| Deputy General Manager | 2.7yrs | CN¥410.00k | 0.12% CN¥ 3.4m | |
| Deputy General Manager | 2.7yrs | CN¥850.00k | 0.081% CN¥ 2.2m | |
| Accounting Supervisor | no data | no data | no data |
2.7yrs
Average Tenure
42yo
Average Age
Experienced Management: 301093's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | 15.2yrs | CN¥1.03m | 6.01% CN¥ 166.6m | |
| Deputy GM & Director | 8yrs | CN¥445.10k | 0.23% CN¥ 6.3m | |
| Independent Director | 6.2yrs | CN¥65.00k | no data | |
| Non Independent Director | 15.2yrs | CN¥1.21m | 0.14% CN¥ 3.8m | |
| Non Independent Director | 7.3yrs | no data | no data | |
| Non Independent Director | 6.2yrs | no data | no data | |
| Non Independent Director | 7.3yrs | no data | no data | |
| Independent Director | 2.8yrs | CN¥65.00k | no data | |
| Independent Director | 2.8yrs | CN¥65.00k | no data | |
| Employee Representative Supervisor | 6.2yrs | no data | no data | |
| Chairman of the Supervisory Board | 2.8yrs | no data | no data | |
| Employee Representative Supervisor | 2.8yrs | no data | no data |
6.2yrs
Average Tenure
43.5yo
Average Age
Experienced Board: 301093's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:41 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Dai | Huatai Research |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |